# Parallel Biology Research Report

**Generated:** 2026-02-19 01:52:16  
**Model:** gpt-5.2-codex  
**Mode:** parallel (5 agents)  
**Status:** All succeeded

---

## Q1: crispr-cas13d

**Question:** What are the latest advances (2024-2025) in CRISPR-Cas13d RNA editing for treating neurodegenerative diseases? Summarize key papers, clinical trials, and remaining delivery challenges.

Below is a focused 2024–2025 update on **CRISPR‑Cas13d (CasRx) RNA targeting/editing** in neurodegenerative disease, emphasizing ALS/FTD (C9orf72) where the most concrete progress exists.

**Scope Note**
Cas13d is an RNA‑guided RNase; in neurodegeneration the 2024–2025 advances are primarily **RNA knockdown of toxic repeat transcripts** (not permanent DNA editing). The strongest new work is in **C9orf72 ALS/FTD**, which has both sense and antisense toxic RNAs and dipeptide repeat (DPR) proteins. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/))

**Key Papers (2024–2025)**
1. **2024 JCI – Optimized Cas13d against structured C9orf72 repeat RNA**
   - Optimized Cas13d gRNAs can target the G4C2 repeat RNA and **reduce DPR production** (poly‑GP/GA) in **patient‑derived iPSCs and motor neurons**, and in **C9‑500 BAC mice**. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/?utm_source=openai))  
   - In vivo delivery used **AAV9 intracerebroventricular (ICV) injection at P0**, with significant DPR reduction in the C9‑500 model. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/))  
   - The paper also reports that **RAN‑translation suppression can occur even when RNA cleavage is limited**, highlighting complex mechanisms and the need for careful guide design and mechanistic validation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/?utm_source=openai))  

2. **2025 Nature Communications – High‑fidelity Cas13d for C9orf72 ALS/FTD**
   - Introduces a **high‑fidelity Cas13 system** with **reduced collateral effects** and **improved transcriptome‑wide specificity**. ([nature.com](https://www.nature.com/articles/s41467-024-55548-5))  
   - In a C9orf72 rodent model, the platform **reduced repeat‑containing RNA**, **lowered RNA foci and DPRs**, and **reversed transcriptional deficits**, while **sparing normal C9orf72 levels**. ([nature.com](https://www.nature.com/articles/s41467-024-55548-5))  
   - Notes RfxCas13d (CasRx) is compact enough for **single‑AAV delivery to CNS**, which is a practical advantage for gene therapy packaging. ([nature.com](https://www.nature.com/articles/s41467-024-55548-5))  

3. **2025 Nature Communications – Dual‑targeting CasRx for sense + antisense C9orf72 RNAs**
   - Demonstrates **multiplexed targeting** of **both sense and antisense repeat RNAs** using Cas13d guide arrays (single construct). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39779704/))  
   - In **patient‑derived iPSC neurons**, CasRx **reduced endogenous repeat RNAs and DPRs** and **protected against glutamate‑induced excitotoxicity**. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39779704/))  
   - **AAV delivery** in two C9orf72 mouse models **reduced sense and antisense repeat transcripts** in vivo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39779704/))  

**Clinical Trials (2024–2025)**
- **No neurodegenerative Cas13d trials** are publicly registered as of the latest 2024–2025 ClinicalTrials.gov updates I could find. The only Cas13 RNA‑targeting trials I located are in **neovascular AMD** (HG202) using high‑fidelity Cas13 via AAV. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06031727?utm_source=openai))  
- This strongly suggests **Cas13d neurodegeneration programs remain preclinical** despite rapid progress in ALS/FTD models.

**Remaining Delivery and Safety Challenges**
- **CNS delivery across the BBB remains a major bottleneck.** Vector engineering is still evolving; 2024 work reports **new CNS‑tropic AAV variants** with markedly improved brain transduction and reduced liver targeting in mice, underscoring active efforts to solve CNS delivery. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38297833/))  
- **Current Cas13d neurodegeneration studies rely on direct CNS viral delivery** (AAV9 ICV P0 or AAV in mouse models), which is effective in rodents but not yet validated for adult human brain delivery at therapeutic scale. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/))  
- **Collateral activity and off‑target RNA knockdown** remain a known risk for Cas13d. A 2025 NAR analysis highlights collateral cleavage and guide‑design constraints (e.g., linear isoform knockdown when targeting circular RNAs), emphasizing safety risks that must be mitigated clinically. ([academic.oup.com](https://academic.oup.com/nar/article/doi/10.1093/nar/gkaf1447/8417327?utm_source=openai))  
- **Structured repeat RNAs** (like G4C2) are intrinsically hard to target; 2024 work shows optimization is required and mechanisms may include **translation suppression beyond direct RNA cleavage**, adding complexity for dose/guide selection. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/?utm_source=openai))  
- **Specificity improvements are promising but must scale.** The 2025 high‑fidelity Cas13d system shows improved specificity and reduced collateral effects in models, but it remains preclinical. ([nature.com](https://www.nature.com/articles/s41467-024-55548-5))  

**Bottom Line (2024–2025)**
- The **most important advances** are in **C9orf72 ALS/FTD**:  
  - targeting **structured repeat RNAs**,  
  - **multiplexed sense+antisense targeting**,  
  - and **high‑fidelity Cas13d variants** with improved specificity and in vivo efficacy.  
- **Clinical translation has not yet reached neurodegenerative trials**, and **delivery (BBB, cell‑type targeting, and systemic safety)** remains the core hurdle.

**Sources**
- `https://pmc.ncbi.nlm.nih.gov/articles/PMC11527445/`  
- `https://www.nature.com/articles/s41467-024-55548-5`  
- `https://pubmed.ncbi.nlm.nih.gov/39779704/`  
- `https://clinicaltrials.gov/study/NCT06031727`  
- `https://clinicaltrials.gov/study/NCT06623279`  
- `https://academic.oup.com/nar/article/doi/10.1093/nar/gkaf1447/8417327`  
- `https://pubmed.ncbi.nlm.nih.gov/38297833/`

If you want, I can also map these advances onto specific disease targets (ALS/FTD vs HD vs AD) and propose which **delivery platforms** are most realistic for each in the next 2–3 years.

---

## Q2: alphafold3-ppi

**Question:** How does AlphaFold 3 improve prediction of protein-protein interactions compared to AlphaFold 2? Describe the architectural changes, new training data, and benchmark results on recent CASP/CAPRI targets.

**Summary**  
AlphaFold 3 (AF3) improves protein–protein interaction (PPI) prediction over AlphaFold 2 (AF2) primarily by replacing AF2’s residue‑frame structure module with an all‑atom diffusion generator and by simplifying the MSA‑heavy trunk into a pair‑centric architecture, while broadening training to multi‑component complexes (proteins plus nucleic acids, ligands, ions, modifications). These changes enable more direct modeling of interface geometry and heterogeneous chemistry, and AF3 reports higher PPI/antibody–antigen accuracy than AlphaFold‑Multimer v2.3 on recent PDB evaluations. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  

**Architectural Changes That Matter for PPIs**  
1. AF2 core: an Evoformer trunk that jointly updates MSA and pair representations, followed by a structure module that builds per‑residue rigid frames and side‑chain torsions; accuracy depends strongly on MSA depth and drops when heterotypic (inter‑chain) contacts dominate. ([nature.com](https://www.nature.com/articles/s41586-021-03819-2))  
2. AF3 trunk redesign: MSA processing is de‑emphasized and the Evoformer is replaced by a simpler “pairformer” that operates mainly on pair and single representations; the MSA representation is not retained, and the number of MSA blocks is reduced. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  
3. AF3 structure generation: the AF2 structure module is replaced by a diffusion module that directly predicts raw atomic coordinates, enabling multi‑scale refinement and reducing the need for special‑casing chemical bonds—important for precise interface geometry across diverse complexes. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  

**Training Data and Inputs (What’s New vs AF2)**  
1. AF3 trains on PDB assemblies and templates while explicitly incorporating broader chemical components (via the Chemical Components Dictionary), enabling complexes that include non‑protein entities; training excludes structures released after 30 Sep 2021. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  
2. AF3’s reported general‑purpose evaluation uses a “recent PDB” set of 8,856 complexes released between 1 May 2022 and 12 Jan 2023 (low‑homology filters applied), giving a modern, interface‑rich benchmark for PPI and antibody–antigen accuracy. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  
3. AF3’s evaluation metrics for PPIs include DockQ‑based interface success (percentage DockQ > 0.23) for protein–protein and protein–antibody interfaces, aligning with CAPRI‑style assessment. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  

**Benchmarks on Recent CASP/CAPRI Targets**  
1. CASP15–CAPRI (Round 54; 2022 targets): 37 targets (14 homodimers, 3 homotrimers, 13 heterodimers including 3 antibody–antigen, 7 large assemblies). High‑quality models reached ~40% of targets vs ~8% two years earlier, largely attributed to broad use of AF2/AF2‑Multimer and their confidence metrics; antibody/nanobody and flexible complexes remained hard. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37905971/))  
2. CASP16–CAPRI (Rounds 57/58; 2024 targets): Round 57 had 34 targets and 47 assessment units. The CAPRI assessment explicitly lists baselines including ColabFold and a manual AlphaFold3 submission, and Round 58 evaluated MassiveFold‑augmented models on a subset, indicating AF3 is now a reference point in the most recent blind PPI evaluations. ([capri-docking.org](https://www.capri-docking.org/assessment/))  
3. AF3 paper benchmarks: AF3 reports higher antibody–antigen accuracy than AlphaFold‑Multimer v2.3 and improved protein–protein interface success on the recent PDB set, using DockQ‑style interface success metrics. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  

**What This Means for PPI Accuracy vs AF2**  
1. AF2’s PPI predictions largely depend on co‑evolutionary signals from deep MSAs and struggle when inter‑chain contacts dominate or MSAs are shallow; this limitation is prominent in antibody‑antigen and flexible complexes seen in CASP/CAPRI. ([nature.com](https://www.nature.com/articles/s41586-021-03819-2))  
2. AF3 targets these gaps by shifting to a diffusion‑based, all‑atom interface generator and simplifying MSA reliance, while training on broader complex chemistries; this yields measurable gains over AF‑Multimer v2.3 on protein–protein and antibody–antigen interface benchmarks and positions AF3 as a baseline in CASP16‑CAPRI. ([nature.com](https://www.nature.com/articles/s41586-024-07487-w))  

If you want, I can drill into specific CASP15/16 targets or pull the per‑target CAPRI score files and summarize where AF3‑based baselines succeed or fail.

**Sources**
```text
https://www.nature.com/articles/s41586-024-07487-w
https://www.nature.com/articles/s41586-021-03819-2
https://pubmed.ncbi.nlm.nih.gov/37905971/
https://www.capri-docking.org/assessment/
```

---

## Q3: single-cell-spatial

**Question:** What are the current state-of-the-art spatial transcriptomics methods (e.g., MERFISH, Visium HD, Stereo-seq) and how are they being combined with single-cell RNA-seq to build whole-organ cell atlases?

Below is a concise, up‑to‑date overview of **state‑of‑the‑art spatial transcriptomics** and **how these platforms are combined with sc/snRNA‑seq to build whole‑organ cell atlases**, with citations to primary papers, evaluations, and open‑access reviews.

**Summary**  
State‑of‑the‑art spatial transcriptomics now spans two complementary families: **high‑plex imaging** (MERFISH/seqFISH+/Xenium/CosMx) that achieves single‑cell or subcellular resolution but is usually targeted, and **sequencing‑based capture** (Visium HD, Stereo‑seq, Slide‑seqV2) that achieves transcriptome‑wide profiling with high spatial resolution and larger tissue coverage. Combining these with sc/snRNA‑seq enables cell‑type mapping, deconvolution, transcriptome imputation, and 3D atlas reconstruction across whole organs. ([bmcgenomics.biomedcentral.com](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3))

---

**State‑of‑the‑Art Methods (selected)**

| Method | Modality | Typical resolution / scale | Gene coverage | Notes / representative refs |
|---|---|---|---|---|
| **MERFISH** | Imaging (smFISH with error‑robust barcoding) | Single‑cell, subcellular | 10^2–10^4 targeted genes | Original MERFISH method and later 10k‑gene implementation; scalable and quantitative. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25858977/?utm_source=openai)) |
| **seqFISH+** | Imaging (sequential FISH) | Single‑cell, subcellular | ~10,000 genes | Demonstrated transcriptome‑scale imaging in mouse brain. ([nature.com](https://www.nature.com/articles/s41586-019-1049-y?utm_source=openai)) |
| **Xenium In Situ** | Imaging (ISS/ISH hybrid) | Subcellular | Targeted panels (hundreds–thousands) | ISS‑style padlock probes + imaging cycles; independent evaluation shows high specificity and subcellular resolution. ([bmcgenomics.biomedcentral.com](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3)) |
| **CosMx SMI** | Imaging (cyclic barcoded probes) | Subcellular, 3D | Targeted RNA + protein | High‑plex RNA+protein imaging in FFPE with subcellular localization. ([nature.com](https://www.nature.com/articles/s41587-022-01483-z?utm_source=openai)) |
| **STARmap** | Imaging (in situ sequencing) | Single‑cell, 3D | 10^2–10^3 genes | 3D intact‑tissue RNA sequencing with cellular resolution. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29930089/?utm_source=openai)) |
| **Visium HD** | Sequencing‑based capture | **2 µm** feature size | Whole‑transcriptome | HD slide feature size reported in comparative review; designed for high‑resolution whole‑transcriptome capture. ([bmcgenomics.biomedcentral.com](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3)) |
| **Stereo‑seq** | Sequencing‑based capture on DNB arrays | **0.22 µm** feature size; large field‑of‑view | Whole‑transcriptome | DNB‑array platform; large FOV at cellular resolution used for organogenesis atlases. ([bmcgenomics.biomedcentral.com](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3)) |
| **Slide‑seqV2** | Sequencing‑based capture | ~10 µm | Whole‑transcriptome | Near‑cellular resolution with improved sensitivity. ([nature.com](https://www.nature.com/articles/s41587-020-0739-1?utm_source=openai)) |

---

**How sc/snRNA‑seq + Spatial Are Combined for Whole‑Organ Atlases**

1. **Reference cell‑type atlases from sc/snRNA‑seq**  
   Large sc/snRNA‑seq datasets define cell types and markers. These references are then used to design targeted spatial panels (MERFISH/Xenium/CosMx) and to annotate spatial data. The whole‑mouse‑brain MERFISH atlas explicitly used scRNA‑seq to select markers and integrate spatial cell types. ([nature.com](https://www.nature.com/articles/s41586-023-06808-9?utm_source=openai))

2. **Deconvolution for spot‑based platforms (Visium/Slide‑seq)**  
   Spatial spots often contain multiple cells; deconvolution uses scRNA‑seq signatures to estimate cell‑type proportions per spot. Widely used methods include:  
   - **RCTD** (robust decomposition) ([nature.com](https://www.nature.com/articles/s41587-021-00830-w?utm_source=openai))  
   - **cell2location** (Bayesian mapping of fine‑grained cell types) ([nature.com](https://www.nature.com/articles/s41587-021-01139-4?utm_source=openai))  
   - **DestVI** (continuous states within cell types) ([nature.com](https://www.nature.com/articles/s41587-022-01272-8?utm_source=openai))  
   - **Stereoscope** (probabilistic cell‑type mapping) ([nature.com](https://www.nature.com/articles/s42003-020-01247-y?utm_source=openai))  

3. **Cell‑level mapping and transcriptome imputation**  
   For single‑cell imaging or higher‑resolution spatial data, scRNA‑seq can be mapped into tissue to impute missing genes and align cell states:  
   - **Tangram** aligns sc/snRNA‑seq to spatial measurements (MERFISH, STARmap, Visium). ([nature.com](https://www.nature.com/articles/s41592-021-01264-7?utm_source=openai))  
   - **SpatialScope** and related generative methods infer transcriptome‑wide expression from spatial data using scRNA‑seq priors. ([nature.com](https://www.nature.com/articles/s41467-023-43629-w?utm_source=openai))  

4. **3D and whole‑organ reconstruction**  
   Serial sections are integrated with sc/snRNA‑seq references to build 3D atlases (registration, label transfer, and imputation across sections). Whole‑organ atlases increasingly combine **high‑resolution spatial** with **large sc/snRNA‑seq references** to achieve organ‑scale coverage.

---

**Examples of Whole‑Organ or Organ‑Scale Atlases Built by Spatial + sc/snRNA‑seq**

1. **Whole mouse brain MERFISH atlas (BICCN)**  
   MERFISH spatial mapping integrated with massive scRNA‑seq to define >5,000 clusters and spatial organization across the whole brain. ([nature.com](https://www.nature.com/articles/s41586-023-06808-9?utm_source=openai))

2. **Whole mouse brain Stereo‑seq atlas (Neuron 2025)**  
   Stereo‑seq + snRNA‑seq produced a single‑cell‑resolution spatial atlas of the entire brain. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0896627325001333?utm_source=openai))

3. **Mouse organogenesis atlas (Stereo‑seq)**  
   Stereo‑seq was used for large field‑of‑view, cellular‑resolution mapping of developing organs across embryogenesis. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0092867422003993))

4. **Regenerating zebrafish heart atlas**  
   Stereo‑seq + scRNA‑seq integrated into an organ‑wide, spatiotemporal atlas of heart regeneration. ([nature.com](https://www.nature.com/articles/s41467-025-59070-0?utm_source=openai))

5. **Whole‑embryo spatial mapping with Slide‑seq**  
   Slide‑seq applied to whole embryos to build spatial maps of early organogenesis stages. ([nature.com](https://www.nature.com/articles/s41588-023-01435-6?utm_source=openai))

---

**Key Takeaways for Atlas‑Building**

1. **Imaging platforms (MERFISH/seqFISH+/Xenium/CosMx)** excel at **single‑cell spatial precision** and detecting targeted gene panels; they are often paired with scRNA‑seq to **impute missing genes** and to **transfer fine cell‑state labels**. ([nature.com](https://www.nature.com/articles/s41586-019-1049-y?utm_source=openai))

2. **Sequencing‑based platforms (Visium HD/Stereo‑seq/Slide‑seqV2)** offer **transcriptome‑wide profiling** with high spatial resolution and large fields of view, but still require scRNA‑seq‑based **cell‑type deconvolution** or **cell mapping** to resolve cellular mixtures. ([bmcgenomics.biomedcentral.com](https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3))

3. **Whole‑organ atlases now routinely combine**:  
   - large sc/snRNA‑seq references,  
   - spatial data for localization,  
   - and algorithmic mapping/deconvolution,  
   yielding **cell‑type resolved spatial atlases** at organ scale. ([nature.com](https://www.nature.com/articles/s41586-023-06808-9?utm_source=openai))

---

If you want, I can also provide a **comparison matrix tailored to a specific organ** (brain, heart, kidney, tumor) or highlight **current best‑practice integration pipelines** with recommended software stacks.

---

## Q4: tp53-gof-mutations

**Question:** Explain the gain-of-function mechanisms of TP53 missense mutations (R175H, R248W, R273H) in cancer. What are the newest therapeutic strategies targeting mutant p53, including molecular glues and PROTACs reported in 2024-2025?

I’m using the **web-search** skill because you asked for the most recent, authoritative sources and specific citations.

**Overview**  
TP53 missense mutations in the DNA‑binding domain often accumulate to high levels (due to loss of normal feedback control) and act as dominant‑negative inhibitors of any remaining wild‑type p53, while also acquiring neomorphic gain‑of‑function (GOF) activities. These GOF activities include altered transcriptional programs via interactions with other proteins and RNAs, promoting proliferation, migration/invasion, immune modulation, and metabolic rewiring. ([nature.com](https://www.nature.com/articles/s41589-025-02051-7))

**Gain‑of‑Function Mechanisms of R175H, R248W, R273H**  
Below is a mutation‑specific summary that separates **structural (conformational)** vs **DNA‑contact** classes and highlights experimentally supported GOF outputs.

| Mutation | Class (DBD) | Key GOF Mechanisms (selected evidence) |
|---|---|---|
| **R175H** | **Conformational/structural mutant** that destabilizes the DBD and alters protein folding. ([nature.com](https://www.nature.com/articles/cddis2017376)) | Promotes cell scattering, migration, and invasion (GOF metastasis phenotypes); shares transcriptional repression of **KLF6/E‑cadherin** with other hotspots, linking to EMT‑like behavior. ([nature.com](https://www.nature.com/articles/cddis2017376)) |
| **R248W** | **DNA‑contact mutant** that disrupts direct DNA binding. ([nature.com](https://www.nature.com/articles/cddis2017376)) | Drives cell mobility/invasion phenotypes similar to R175H/R273H; also suppresses **KLF6/E‑cadherin** in hotspot‑mutant contexts, supporting EMT‑like migration. ([nature.com](https://www.nature.com/articles/cddis2017376)) Additional GOF example: R248W (and R273H) promote stemness and 5‑FU chemoresistance in colorectal cancer via **TCF21/CD44** axis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35071232/?utm_source=openai)) |
| **R273H** | **DNA‑contact mutant** that directly impairs DNA binding. ([nature.com](https://www.nature.com/articles/cddis2017376)) | Potently enhances migration/invasion and metastasis. Mechanistically, it represses **DLX2**, leading to **NRP2** upregulation and increased cell mobility/metastasis. ([nature.com](https://www.nature.com/articles/cddis2017376)) It also activates **EGFR‑AKT‑FOXO1** signaling to suppress **KLF6** and **E‑cadherin**, driving EMT and migration. ([nature.com](https://www.nature.com/articles/s41419-020-02814-1)) |

**Newest Therapeutic Strategies Targeting Mutant p53 (2024‑2025)**  
The 2024–2025 literature has emphasized **allele‑specific reactivation**, **targeted degradation (PROTACs)**, **molecular glue stabilization**, and **induced‑proximity cytotoxic strategies**.

**1. PROTACs and Targeted Degradation (mutant‑selective)**  
- **R175H‑selective aptamer‑PROTAC (dp53m, 2024)**: A DNA aptamer binder was engineered and linked to a PROTAC, selectively degrading **p53‑R175H** via the ubiquitin‑proteasome system while sparing wild‑type p53; shows in vitro and in vivo antitumor activity and cisplatin sensitization. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2095927324003517))  
- **Peptide‑based R175H PROTACs (2024)**: Peptide ligands for R175H coupled to VHL‑recruiting motifs induce degradation of p53‑R175H and reduce migration/invasion. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39554460/))  
- **Small‑molecule–induced Y220C degradation (2025)**: Cabozantinib disrupts **p53‑Y220C–USP7** interaction, enabling CHIP‑mediated ubiquitination and proteasomal degradation with preferential activity in Y220C‑mutant cells. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39793887/))

**2. Molecular Glues (2024)**  
- **USP7‑engaging molecular glues (2024)**: Screening identified small molecules (including bromocriptine) that act as molecular glues to tether p53 to **USP7**, stabilizing p53 and suppressing tumor growth in xenografts. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2095927324002512))  
  **Interpretation:** These are **p53‑stabilizing** glues rather than degraders. For GOF mutant p53, stabilization could be harmful unless combined with reactivation or engineered for mutant‑selective context; this is an inference based on GOF biology rather than a direct claim in the glue paper. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2095927324002512))

**3. Allele‑Specific Reactivators / Refolders**  
- **Rezatapopt (PC14586) for Y220C (Cancer Discovery 2025)**: Structural correction of Y220C restores DNA binding and wild‑type‑like transcriptional programs; preclinical activity and **registrational phase II** clinical evaluation reported. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39945593/))  
- **Covalent fragment stabilizers (ACS PTS 2024)**: Covalent fragments (SN001/SN006/SN007) bind the Y220C pocket and stabilize the mutant DBD, with X‑ray evidence of Cys220 engagement and thermal stabilization. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39698266/?utm_source=openai))  
- **pCAP‑250 reactivating peptide (Cell Death & Differentiation 2024)**: Reactivating peptide reduces mutant p53 accumulation and mitigates LOH‑associated phenotypes in R248Q LFS fibroblasts, suggesting a preventive/reactivating strategy. ([nature.com](https://www.nature.com/articles/s41418-024-01307-4))

**4. Proximity‑Inducing Cytotoxic Strategies (2025)**  
- **Mutant p53 abundance as a targeting handle**: A bifunctional molecule that binds **p53‑Y220C** and recruits a **PLK1 inhibitor** forms a ternary complex and selectively kills TP53‑mutant cells by proximity‑driven PLK1 inhibition, independent of p53 transcriptional activity. ([nature.com](https://www.nature.com/articles/s41589-025-02051-7))  
  This is a notable 2025 strategy that may be applicable to other missense mutants where refolding is difficult. ([nature.com](https://www.nature.com/articles/s41589-025-02051-7))

**Implications Specifically for R175H, R248W, R273H**  
- **R175H (structural)**: 2024 PROTACs provide the most mutation‑directed degradation data, making degradation a leading near‑term strategy for this allele. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2095927324003517))  
- **R248W & R273H (contact mutants)**: Because these alter direct DNA contacts, refolding can be intrinsically harder; strategies that **degrade mutant p53** or **use mutant‑specific proximity approaches** may be more tractable than refolding alone. ([nature.com](https://www.nature.com/articles/s41589-025-02051-7))  
- **GOF pathway targeting**: Mechanistic nodes such as **KLF6/E‑cadherin**, **DLX2‑NRP2**, and **EGFR‑AKT‑FOXO1** suggest pathway‑directed combination therapies tailored to specific mutant programs. ([nature.com](https://www.nature.com/articles/cddis2017376))

---

**Sources**  
1. `https://www.nature.com/articles/cddis2017376`  
2. `https://www.nature.com/articles/s41419-020-02814-1`  
3. `https://pubmed.ncbi.nlm.nih.gov/35071232/`  
4. `https://pubmed.ncbi.nlm.nih.gov/37449494/`  
5. `https://www.sciencedirect.com/science/article/pii/S2095927324002512`  
6. `https://www.sciencedirect.com/science/article/pii/S2095927324003517`  
7. `https://pubmed.ncbi.nlm.nih.gov/39554460/`  
8. `https://pubmed.ncbi.nlm.nih.gov/39793887/`  
9. `https://pubmed.ncbi.nlm.nih.gov/39945593/`  
10. `https://pubmed.ncbi.nlm.nih.gov/39698266/`  
11. `https://pmc.ncbi.nlm.nih.gov/articles/PMC11651176/`  
12. `https://www.nature.com/articles/s41418-024-01307-4`  
13. `https://www.nature.com/articles/s41589-025-02051-7`

---

## Q5: long-read-pangenome

**Question:** How are long-read sequencing technologies (PacBio HiFi, ONT) being used to build the human pangenome reference? Summarize the HPRC achievements, structural variant discovery, and clinical implications.

Using the **web-search** skill because the task requires up‑to‑date, authoritative sources with citations.

**Summary**
Long‑read sequencing (PacBio HiFi and Oxford Nanopore Technologies, ONT) is the backbone of the Human Pangenome Reference Consortium (HPRC) effort: it enables phased, near‑complete diploid assemblies across diverse individuals, which are then integrated into graph‑based pangenomes. The 2023 draft pangenome (Release 1) established the core approach and quantified large gains in structural‑variant (SV) discovery and small‑variant accuracy versus a linear reference. Release 2 (announced May 12, 2025) scaled to >200 samples with improved assembly accuracy and richer functional annotations, and Release 3 is planned for Summer 2026 with >350 assemblies. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))

**How PacBio HiFi and ONT are used to build the human pangenome**
1. **High‑accuracy, haplotype‑resolved assemblies**
   - PacBio HiFi provides highly accurate long reads that support base‑level accuracy and robust assembly of diploid haplotypes; ONT ultra‑long reads span repeats and structurally complex regions, improving contiguity and structural correctness. The HPRC integrates HiFi, ONT, and proximity‑ligation data (Hi‑C/Omni‑C) to generate phased, near telomere‑to‑telomere assemblies with reduced error rates. ([humanpangenome.org](https://www.humanpangenome.org/release-timeline/?utm_source=openai))  
2. **Graph‑based pangenome construction**
   - Release 1 provides pangenomes built with multiple graph approaches (Minigraph, Minigraph‑Cactus, and PGGB), enabling both SV‑focused and base‑level representations of variation across haplotypes. ([humanpangenome.org](https://www.humanpangenome.org/data/?utm_source=openai))  
   - The Minigraph‑Cactus method is a key pipeline for constructing pangenome graphs from multiple assemblies, supporting scalable, graph‑based representation of long‑read assemblies. ([nature.com](https://www.nature.com/articles/s41587-023-01793-w?utm_source=openai))  
3. **Public data and annotations**
   - Release 2 data include PacBio HiFi, ONT ultra‑long reads, PacBio Kinnex transcriptome data, and Omni‑C, with assemblies produced (notably) using Hifiasm and annotation layers added across samples. ([humanpangenome.org](https://www.humanpangenome.org/data/?utm_source=openai))  

**HPRC achievements and releases**
1. **Release 1 (May 2023)**
   - 47 phased, diploid assemblies (94 haplotypes) from diverse individuals. Assemblies were >99% complete and >99% accurate at structural and base‑pair levels. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))  
   - Added ~119 Mb of euchromatic sequence and >1,100 gene duplications relative to GRCh38; ~90 Mb of new sequence came from structural variation. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))  
   - Pangenome‑based analyses reduced small‑variant errors by ~34% and more than doubled detected SVs per haplotype compared with GRCh38 pipelines. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))  
2. **Release 2 (announced May 12, 2025)**
   - Expanded to >200 samples (>400 haplotypes), integrating improved assembly algorithms that combine HiFi, ONT, and Hi‑C/Omni‑C to increase contiguity and structural accuracy, plus additional polishing that reduces SNV/indel errors by more than half for most sequences. ([humanpangenome.org](https://www.humanpangenome.org/release-timeline/?utm_source=openai))  
   - Adds long‑read transcriptome (HiFi) annotations for most samples, as well as public methylation data. ([humanpangenome.org](https://www.humanpangenome.org/release-timeline/?utm_source=openai))  
3. **Release 3 (planned for Summer 2026)**
   - Targeting >350 assemblies (>700 haplotypes) with essentially complete telomere‑to‑telomere haplotypes. This is a forward‑looking milestone and not yet released as of February 19, 2026. ([humanpangenome.org](https://www.humanpangenome.org/release-timeline/?utm_source=openai))  

**Structural‑variant discovery: what long reads + pangenomes changed**
1. **Large SV yield and sequence‑resolved alleles**
   - The draft pangenome (Release 1) demonstrated a ~104% increase in SV detection per haplotype vs GRCh38‑based workflows, indicating that pangenome graphs expose SV alleles otherwise missed in linear reference analyses. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))  
2. **Population‑scale SV resources enabled by long reads**
   - A 2025 Nature study sequencing 1,019 diverse humans with long reads integrated linear and pangenome graph analyses to recover >100,000 sequence‑resolved biallelic SVs and genotype ~300,000 VNTRs, highlighting the power of graph‑aware SV discovery at scale. ([nature.com](https://www.nature.com/articles/s41586-025-09290-7?utm_source=openai))  
3. **Graph‑aware SV discovery pipelines**
   - Graph‑based SV discovery (e.g., using HPRC minigraph graphs) supports detection of SVs absent from a linear reference, and the HPRC graphs are a practical backbone for these analyses. ([nature.com](https://www.nature.com/articles/s41586-025-09290-7?utm_source=openai))  

**Clinical implications**
1. **Reduced reference bias and improved variant calling**
   - Pangenome graphs reduce small‑variant errors and improve SV detection compared with linear reference pipelines, which directly improves clinical variant sensitivity in complex loci and repetitive regions. ([nature.com](https://www.nature.com/articles/s41586-023-05896-x?utm_source=openai))  
2. **Rare disease SV prioritization**
   - In rare‑disease cohorts, pangenome‑graph approaches increase SV detection and improve discrimination of rare vs common alleles, supporting more accurate filtering and prioritization of potentially pathogenic SVs. ([nature.com](https://www.nature.com/articles/s41467-024-44980-2?utm_source=openai))  
3. **Path to more equitable genomic medicine**
   - By incorporating globally diverse haplotypes and building graph references, the HPRC enables analyses less biased toward any single ancestry, supporting more accurate variant interpretation across populations. ([nature.com](https://www.nature.com/articles/s41586-022-04601-8?utm_source=openai))  

**Practical takeaways for researchers and clinicians**
1. **Long reads are now central for reference construction**, not just SV discovery: HiFi delivers base‑level accuracy, ONT ultra‑long reads resolve repeats and complex regions, and Hi‑C/Omni‑C enables chromosome‑scale phasing. ([humanpangenome.org](https://www.humanpangenome.org/release-timeline/?utm_source=openai))  
2. **Graph references are mature enough for real analyses**, with published pipelines (Minigraph‑Cactus, PGGB) and HPRC‑released graphs already supporting SV discovery, genotyping, and read mapping. ([humanpangenome.org](https://www.humanpangenome.org/data/?utm_source=openai))  
3. **Clinical pipelines can benefit today** by using pangenome‑based SV discovery and mapping in complex loci, especially for rare disease cohorts or populations underrepresented in linear references. ([nature.com](https://www.nature.com/articles/s41467-024-44980-2?utm_source=openai))  

**Sources**
1. `https://www.humanpangenome.org/release-timeline/`
2. `https://www.nature.com/articles/s41586-023-05896-x`
3. `https://www.humanpangenome.org/data/`
4. `https://www.humanpangenome.org/population-descriptors/`
5. `https://www.nature.com/articles/s41587-023-01793-w`
6. `https://www.nature.com/articles/s41586-025-09290-7`
7. `https://www.nature.com/articles/s41467-024-44980-2`
8. `https://www.nature.com/articles/s41586-022-04601-8`

---
